Ugbo ala - T

Akụkọ mmepe nke ụgbọ ala - T Cell Cell

Mmepe nke ugbo ala - T cell cell nwere ike ịlaghachi na 1989, mgbe Cross G na atọ ndị ọkà mmụta sayensị atọ na-atụ aro echiche nke "ụgbọ ala". Mgbe ahụ, na 2008, The Cred Hitchison Cancer Institute mbụ ejiri ụgbọ ala T cells iji mesoo B - Cell lymphoma, na-egosi nchekwa nke usoro ọgwụgwọ a. N'afọ 2010, okwu mbụ nke CD19 - na-ezute ụgbọ ala - T ofgwọ ọrịa maka B - Cell - Agụghị Agụụ - Hymphoma gwọtara na United States. Mgbe ahụ na 2011, ọmụmụ paradaịs nke Carl June na Mahadum nke Pennsylvania nwere ọganihu dị ukwuu, akụkọ ọgwụgwọ na-eme nke ọma, na-eme ka ọgwụgwọ sel na-eme ka ọ bụrụ oge mgbawa na-eme ihe ọ bụla. N'afọ 2017, US nri na ọgwụ ọgwụ (FDA) kwadoro ikike ahịa nke ụgbọ ala Tel nke mbụ ụgbọ ala Kympiah, nke akara ọbịbịa nke oge azụmahịa nke ụgbọ ala T. N'otu afọ, a kwadoro ngwaahịa ọgwụgwọ nke abụọ - A na-akwadokwa ngwaahịa ọgwụgwọ nke abụọ - A na-akwadokwa ngwaahịa ọgwụgwọ sel nke abụọ. N'afọ 2020, FDA kwadoro ụgbọ ala nke atọ t - Cell Thelọ Ọrụ Propy Produc Produc. Na 2021, FDA kwadoro ngwaahịa abụọ - T immumotherapy ngwaahịa, Broyanzi na Amecma, maka ọgwụgwọ nke iweghachi B - Cell lymphoma na otutu myoma, n'otu n'otu. N'otu afọ ahụ, CDE site na China kwalitekwara ikike ahịa nke ụgbọ ala abụọ sitere na AXI - Celma - ma maka ọgwụgwọ ndị ọrịa toro eto ma ọ bụ na-emegharị ya buru ibu ma ọ bụ na sel.

Na 2022, FDA kwadoro ikike ahịa nke Carvykti, ụgbọ ala - Tel cell PropAPing na-ezute celluration B Cell Antigen (BCMA) maka ọgwụgwọ nke bacrease ma ọ bụ gbanwee ọtụtụ myoloma.

N'oge a, ọgwụgwọ cell t cell abanyela oge nke mita cancer ma meghee ọmarịcha ihe nchebe n'ụwa.

Gịnị bụ ụgbọ ala - Usoro ọgwụgwọ cell

Usoro ọgwụgwọ ụgbọ ala ụgbọ ala, nke a makwaara dị ka Antitinec recpor t cellimotherapy na-eme ihe mgbochi mkpụrụ nke na-eji mkpụrụ ndụ T vilro. Nke a na-enye ha ohere ịkọwapụta mkpụrụ ndụ tumo na-ajụ nkụ tum ma tinye mkpụrụ ndụ ndị ahụ laghachi na onye ọrịa ahụ ka ọ gwọ ọrịa ahụ.

Iit ID GREE Ulo ogwu Uzo ahia

Ụgbọ ala - t